Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?

Kristin N Kelly; Francisco I Macedo; Nipun B Merchant

doi:10.1016/j.yasu.2020.05.001

Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?

Adv Surg. 2020 Sep:54:49-68. doi: 10.1016/j.yasu.2020.05.001. Epub 2020 Jun 24.

Authors

Kristin N Kelly¹, Francisco I Macedo², Nipun B Merchant³

Affiliations

¹ Division of Surgical Oncology, Dewitt-Daughtry Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, CRB, 4th Floor, Miami, FL 33136, USA.
² Department of Surgery, North Florida Regional Medical Center, University of Central Florida College of Medicine, Gainesville, FL, USA.
³ Division of Surgical Oncology, Dewitt-Daughtry Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, CRB, 4th Floor, Miami, FL 33136, USA. Electronic address: nmerchant@miami.edu.

PMID: 32713439
DOI: 10.1016/j.yasu.2020.05.001

No abstract available

Keywords: Borderline resectable pancreatic cancer; CA 19-9; FOLFIRINOX; Gemcitabine-abraxane; Locally advanced pancreatic cancer; Neoadjuvant chemotherapy; Portal vein resection; Whipple procedure.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Adenocarcinoma / classification
Adenocarcinoma / pathology
Adenocarcinoma / surgery
Adenocarcinoma / therapy*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Margins of Excision
Neoadjuvant Therapy*
Neoplasm Metastasis
Pancreatectomy
Pancreatic Neoplasms / classification
Pancreatic Neoplasms / pathology
Pancreatic Neoplasms / surgery
Pancreatic Neoplasms / therapy*